Lipella Pharmaceuticals Inc. (LIPO)
| Market Cap | 5.78M |
| Revenue (ttm) | 477,449 |
| Net Income (ttm) | -4.74M |
| Shares Out | 7.61M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 56,163 |
| Open | 0.760 |
| Previous Close | 0.762 |
| Day's Range | 0.750 - 0.785 |
| 52-Week Range | 0.640 - 2.710 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 2.00 (+166.31%) |
| Earnings Date | May 28, 2024 |
About LIPO
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (G... [Read more]
Financial Performance
In 2023, LIPO's revenue was $449,617, an increase of 144.15% compared to the previous year's $184,156. Losses were -$4.62 million, 77.8% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for LIPO stock is "Strong Buy" and the 12-month stock price forecast is $2.0.
News
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host dis...
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PITTSBURGH , Oct. 25, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases w...
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
PITTSBURGH , Oct. 24, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases w...
Lipella Pharmaceuticals stock more than doubles in 3 days as FDA approves IND for OLP treatment
Shares of Lipella Pharmaceuticals Inc. LIPO, +51.55% rocketed 52.2% higher in very active tracing Friday, after the Pittsburgh-based biotechnology company's investigational new drug application for it...
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus
LP-310 is an oral formulation of Lipella's lead asset LP-10. PITTSBURGH , Oct. 20, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinic...
Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology
Article highlights results from successful Phase 2a clinical trial for lead candidate, LP-10 Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024 PITTSBURGH, Pa. , Sept. 21, 2023...
Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
Successful top line results from Phase 2a clinical trial for lead candidate LP-10 Oral Health Scientific Advisory Board established to focus on development of LP-310 for oral lichen planus Late-breaki...
Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting
Presentation Focused on Positive Results from Recent Phase 2a Study PITTSBURGH , May 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a c...
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
PITTSBURGH, April 17, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant...
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent
Lipella awarded $1.35m grant in 2022 for development of intravesical contrast-enhanced magnetic resonance imaging (ICE-MRI) technology. PITTSBURGH , April 5, 2023 /PRNewswire/ -- Lipella Pharmaceutica...
Lipella Provides Business Update and Reports 2022 Financial Results
Company Successfully Completes Phase 2a Clinical Trial Fourth Quarter or Full Year Highlights • Appointed Douglas Johnston as CFO in November 2022 • Successfully completed Initial Public Offering, att...
Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association
PITTSBURGH, March 16, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase 2A clinical trial...
Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board
Five-member Board will initially focus on the development of LP-310 PITTSBURGH , March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stag...
Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
Results to be Presented at BIOTECH SHOWCASETM 2023 on Wednesday, January 11 th at 2:00pm PST PITTSBURGH , Jan. 11, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, ...
Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco
PITTSBURGH, Jan. 9, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by...